300485 赛升药业
已收盘 04-08 15:00:00
资讯
新帖
简况
赛升药业（300485）披露子公司取得换发《药品生产许可证》公告，4月7日股价上涨3.72%
证券之星 · 04-07 17:31
赛升药业（300485）披露子公司取得换发《药品生产许可证》公告，4月7日股价上涨3.72%
股市必读：赛升药业（300485）4月3日董秘有最新回复
证券之星 · 04-07 03:22
股市必读：赛升药业（300485）4月3日董秘有最新回复
图解赛升药业年报：第四季度单季净利润同比下降227.07%
证券之星 · 03-30
图解赛升药业年报：第四季度单季净利润同比下降227.07%
赛升药业(300485.SZ)发布2025年度业绩，扭亏为盈至1457.1万元
智通财经 · 03-30
赛升药业(300485.SZ)发布2025年度业绩，扭亏为盈至1457.1万元
太阳制药合作伙伴Philogen肉瘤二期试验未达主要终点
投资观察 · 03-28
太阳制药合作伙伴Philogen肉瘤二期试验未达主要终点
赛升药业：截至2026年3月20日，公司股东户数为32211
证券之星 · 03-26
赛升药业：截至2026年3月20日，公司股东户数为32211
赛升药业（300485）披露子公司撤回达格列净片注册申请公告，3月20日股价下跌2.76%
证券之星 · 03-20
赛升药业（300485）披露子公司撤回达格列净片注册申请公告，3月20日股价下跌2.76%
赛升药业(300485.SZ)子公司撤回一项药品注册申请
智通财经 · 03-20
赛升药业(300485.SZ)子公司撤回一项药品注册申请
太阳药业宣布美国FDA受理ILUMYA®补充生物制剂许可申请 用于治疗成人活动性银屑病关节炎
投资观察 · 03-16
太阳药业宣布美国FDA受理ILUMYA®补充生物制剂许可申请 用于治疗成人活动性银屑病关节炎
股市必读：赛升药业(300485)股东户数3.25万户，较上期减少1.48%
证券之星 · 03-16
股市必读：赛升药业(300485)股东户数3.25万户，较上期减少1.48%
赛升药业(300485)3月10日股东户数3.25万户，较上期减少1.48%
证券之星 · 03-13
赛升药业(300485)3月10日股东户数3.25万户，较上期减少1.48%
赛升药业：截至2026年2月27日，公司股东户数为33028
证券之星 · 03-04
赛升药业：截至2026年2月27日，公司股东户数为33028
股市必读：赛升药业(300485)股东户数3.36万户，较上期减少1.11%
证券之星 · 03-02
股市必读：赛升药业(300485)股东户数3.36万户，较上期减少1.11%
赛升药业：截至2026年2月13日，公司股东户数为33591
证券之星 · 02-27
赛升药业：截至2026年2月13日，公司股东户数为33591
赛升药业(300485)2月10日股东户数3.4万户，较上期增加1.81%
证券之星 · 02-24
赛升药业(300485)2月10日股东户数3.4万户，较上期增加1.81%
赛升药业：关于相关责任保险事宜，公司将遵照监管要求，结合自身经营治理实际情况，统筹研判、适时参保
证券之星 · 02-11
赛升药业：关于相关责任保险事宜，公司将遵照监管要求，结合自身经营治理实际情况，统筹研判、适时参保
赛升药业：截至2026年1月30日，公司股东户数为33365
证券之星 · 02-05
赛升药业：截至2026年1月30日，公司股东户数为33365
股市必读：赛升药业（300485）预计2025年全年扣非后净利润亏损2347.07万元至2868.64万元
证券之星 · 02-02
股市必读：赛升药业（300485）预计2025年全年扣非后净利润亏损2347.07万元至2868.64万元
赛升药业（300485）披露2025年度业绩预告，1月30日股价下跌0.9%
证券之星 · 01-30
赛升药业（300485）披露2025年度业绩预告，1月30日股价下跌0.9%
赛升药业(300485)1月20日股东户数3.41万户，较上期减少0.04%
证券之星 · 01-26
赛升药业(300485)1月20日股东户数3.41万户，较上期减少0.04%
加载更多
公司概况
公司名称：
北京赛升药业股份有限公司
所属行业：
医药制造业
上市日期：
2015-06-26
主营业务：
北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药、其他药品、其他业务。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。
发行价格：
38.46
{"stockData":{"symbol":"300485","market":"SZ","secType":"STK","nameCN":"赛升药业","latestPrice":11.41,"timestamp":1775631786000,"preClose":11.7,"halted":0,"volume":20623186,"delay":0,"changeRate":-0.0248,"floatShares":274000000,"shares":482000000,"eps":0.2035,"marketStatus":"已收盘","change":-0.29,"latestTime":"04-08 15:00:00","open":11.7,"high":11.8,"low":11.36,"amount":237000000,"amplitude":0.0376,"askPrice":11.42,"askSize":821,"bidPrice":11.41,"bidSize":1396,"shortable":0,"etf":0,"ttmEps":0.2035,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775698200000},"marketStatusCode":5,"adr":0,"adjPreClose":11.7,"symbolType":"stock","openAndCloseTimeList":[[1775611800000,1775619000000],[1775624400000,1775631600000]],"highLimit":12.87,"lowLimit":10.53,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":481666400,"isCdr":false,"pbRate":1.67,"roa":"--","peRate":56.068796,"roe":"0.43%","epsLYR":0.03,"committee":0.593557,"marketValue":5496000000,"turnoverRate":0.0753,"status":1,"floatMarketCap":3124000000},"requestUrl":"/m/hq/s/300485","defaultTab":"news","newsList":[{"id":"2625939502","title":"赛升药业（300485）披露子公司取得换发《药品生产许可证》公告，4月7日股价上涨3.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625939502","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625939502?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:31","pubTimestamp":1775554260,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，赛升药业报收于11.7元，较前一交易日上涨3.72%，最新总市值为56.35亿元。该股当日开盘11.36元，最高11.71元，最低10.85元，成交额达2.45亿元，换手率为7.89%。近日，北京赛升药业股份有限公司子公司沈阳君元药业有限公司收到辽宁省药品监督管理局换发的《药品生产许可证》，许可证有效期至2031年3月24日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","300485","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625785606","title":"股市必读：赛升药业（300485）4月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2625785606","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625785606?lang=zh_cn&edition=full","pubTime":"2026-04-07 03:22","pubTimestamp":1775503333,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，赛升药业报收于11.28元，下跌3.75%，换手率7.85%，成交量21.5万手，成交额2.48亿元。董秘最新回复投资者： 请问截至2026年3月 31日公司的股东总数是多少？谢谢董秘： 您好，截至2026年3月31日，公司股东户数为32386。交易信息汇总资金流向4月3日主力资金净流出485.74万元，占总成交额1.96%；游资资金净流出2079.26万元，占总成交额8.37%；散户资金净流入2564.99万元，占总成交额10.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700002201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0046","300485","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623313130","title":"图解赛升药业年报：第四季度单季净利润同比下降227.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623313130","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623313130?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:33","pubTimestamp":1774863209,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业2025年年报显示，当年度公司主营收入4.05亿元，同比下降2.82%；归母净利润1457.1万元，同比上升121.16%；扣非净利润-2699.04万元，同比下降329.51%；其中2025年第四季度，公司单季度主营收入9609.13万元，同比上升2.66%；单季度归母净利润-3728.86万元，同比下降227.07%；单季度扣非净利润-2276.76万元，同比下降293.4%；负债率4.93%，投资收益2853.87万元，财务费用-85.25万元，毛利率65.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000024131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623318821","title":"赛升药业(300485.SZ)发布2025年度业绩，扭亏为盈至1457.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623318821","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623318821?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:57","pubTimestamp":1774861044,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)发布2025年年度报告，该公司营业收入为4.05亿元，同比减少2.82%。归属于上市公司股东的净利润为1457.1万元。归属于上市公司股东的扣除非经常性损益的净亏损为2699.04万元。基本每股收益为0.03元。此外，拟向全体股东每10股派发现金红利0.3元(含税)。报告期内公司积极推进临床短缺及易短缺产品的生产及销售，以及凉水河二街厂区验证进度，加快产品场地变更、技术转移以及GMP符合性检查等工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"赛升药业(300485.SZ)发布2025年度业绩，扭亏为盈至1457.1万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300485","BK0028","BK0012","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134152392","title":"太阳制药合作伙伴Philogen肉瘤二期试验未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1134152392","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134152392?lang=zh_cn&edition=full","pubTime":"2026-03-28 03:14","pubTimestamp":1774638866,"startTime":"0","endTime":"0","summary":"太阳制药宣布，其合作伙伴Philogen公司在软组织肉瘤领域开展的二期FLASH研究未能达到主要临床终点。与此同时，Philogen针对胶质母细胞瘤的二期GLIOSTAR试验同样未实现主要终点目标。\n尽管两项中期研究结果未达预期，Philogen仍表示将坚持推进GLIOSUN临床试验计划的执行。该决定彰显了公司对研发项目的持续投入与信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK0046","300485","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622887272","title":"赛升药业：截至2026年3月20日，公司股东户数为32211","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622887272?lang=zh_cn&edition=full","pubTime":"2026-03-26 11:36","pubTimestamp":1774496178,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)03月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止3月20日公司股东人数是多少？谢谢！赛升药业回复：您好，截至2026年3月20日，公司股东户数为32211。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600018973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","300485","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620732196","title":"赛升药业（300485）披露子公司撤回达格列净片注册申请公告，3月20日股价下跌2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620732196","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620732196?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:32","pubTimestamp":1774017140,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，赛升药业报收于10.58元，较前一交易日下跌2.76%，最新总市值为50.96亿元。该股当日开盘10.88元，最高11.0元，最低10.58元，成交额达5750.63万元，换手率为1.95%。公司于近日披露《关于子公司撤回药品注册申请的公告》。公告显示，北京赛升药业股份有限公司子公司北京赛而生物药业有限公司近日收到国家药品监督管理局下发的《药品注册申请终止通知书》，同意撤回达格列净片的注册申请。此次撤回对公司研发工作及经营业绩无重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0028","BK0012","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620785067","title":"赛升药业(300485.SZ)子公司撤回一项药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2620785067","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620785067?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:15","pubTimestamp":1773994526,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)公告，公司子公司北京赛而生物药业有限公司(简称“赛而生物”)近日收到了国家药品监督管理局下发的《药品注册申请终止通知书》，同意赛而生物撤回达格列净片的注册申请。公告显示，赛而生物于2025年3月向国家药品监督管理局递交达格列净片上市许可申请并获得受理，受政策法规变更等因素影响，需进一步完善申报资料，主动撤回本次申请。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0012","300485","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150027399","title":"太阳药业宣布美国FDA受理ILUMYA®补充生物制剂许可申请 用于治疗成人活动性银屑病关节炎","url":"https://stock-news.laohu8.com/highlight/detail?id=1150027399","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150027399?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:47","pubTimestamp":1773661653,"startTime":"0","endTime":"0","summary":"太阳制药工业有限公司宣布，美国食品药品监督管理局（FDA）已正式受理其ILUMYA®（Tildrakizumab-asmn）的补充生物制剂许可申请（sBLA），该药物拟用于治疗成人活动性银屑病关节炎。\nFDA针对ILUMYA®的sBLA审评截止日期定于2026年10月29日。这一监管里程碑标志着该药物在拓展适应症方面取得重要进展，有望为银屑病关节炎患者提供新的治疗选择。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","BK0028","BK0012","300485","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619448899","title":"股市必读：赛升药业(300485)股东户数3.25万户，较上期减少1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619448899","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619448899?lang=zh_cn&edition=full","pubTime":"2026-03-16 03:07","pubTimestamp":1773601631,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，赛升药业报收于10.9元，上涨0.18%，换手率1.57%，成交量4.31万手，成交额4717.92万元。来自股本股东变化：截至3月10日股东户数环比下降1.48%，筹码集中度有所提升。股本股东变化股东户数变动近日赛升药业披露，截至2026年3月10日公司股东户数为3.25万户，较2月27日减少489.0户，减幅为1.48%。户均持股数量由上期的1.46万股增加至1.48万股，户均持股市值为16.61万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0046","BK0028","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619228160","title":"赛升药业(300485)3月10日股东户数3.25万户，较上期减少1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619228160","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619228160?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:17","pubTimestamp":1773393477,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2026年3月10日公司股东户数为3.25万户，较2月27日减少489.0户，减幅为1.48%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至3月10日，生物制品行业平均股东户数为3.45万户。从股价来看，2026年2月27日至2026年3月10日，赛升药业区间跌幅为1.23%，在此期间股东户数减少489.0户，减幅为1.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300029340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300485","BK0046","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616306492","title":"赛升药业：截至2026年2月27日，公司股东户数为33028","url":"https://stock-news.laohu8.com/highlight/detail?id=2616306492","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616306492?lang=zh_cn&edition=full","pubTime":"2026-03-04 09:01","pubTimestamp":1772586066,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)03月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2月底股东人数有多少赛升药业回复：您好，截至2026年2月27日，公司股东户数为33028。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400008648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300485","BK0012","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616104876","title":"股市必读：赛升药业(300485)股东户数3.36万户，较上期减少1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616104876","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616104876?lang=zh_cn&edition=full","pubTime":"2026-03-02 03:11","pubTimestamp":1772392270,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，赛升药业报收于11.36元，下跌0.18%，换手率1.38%，成交量3.77万手，成交额4275.39万元。交易信息汇总资金流向2月27日主力资金净流出310.12万元；游资资金净流出101.48万元；散户资金净流入411.6万元。股本股东变化股东户数变动近日赛升药业披露，截至2026年2月13日公司股东户数为3.36万户，较2月10日减少377.0户，减幅为1.11%。户均持股数量由上期的1.42万股增加至1.43万股，户均持股市值为16.15万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0239","BK0028","BK0012","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614887317","title":"赛升药业：截至2026年2月13日，公司股东户数为33591","url":"https://stock-news.laohu8.com/highlight/detail?id=2614887317","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614887317?lang=zh_cn&edition=full","pubTime":"2026-02-27 15:51","pubTimestamp":1772178669,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)02月27日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问截止至2月20日（2月13日收盘）公司股东人数为多少，谢谢！赛升药业回复：您好，截至2026年2月13日，公司股东户数为33591。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700022195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485","BK0028","BK0012","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613791386","title":"赛升药业(300485)2月10日股东户数3.4万户，较上期增加1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613791386","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613791386?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:24","pubTimestamp":1771925080,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2026年2月10日公司股东户数为3.4万户，较1月30日增加603.0户，增幅为1.81%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至2月10日，生物制品行业平均股东户数为3.47万户。从股价来看，2026年1月30日至2026年2月10日，赛升药业区间涨幅为5.61%，在此期间股东户数增加603.0户，增幅为1.81%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400032544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0239","BK0046","300485","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610820809","title":"赛升药业：关于相关责任保险事宜，公司将遵照监管要求，结合自身经营治理实际情况，统筹研判、适时参保","url":"https://stock-news.laohu8.com/highlight/detail?id=2610820809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610820809?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:45","pubTimestamp":1770799517,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)02月11日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司没有买董监高责任保险，如果被投资者诉讼，需要支付巨额的赔偿，这个损失谁来承担？赛升药业回复：您好，公司始终严格依据法律法规及规范性文件要求，持续完善法人治理与内控流程；公司董高均勤勉尽责、严格遵守监管规则与公司制度审慎规范履职，全力维护公司及全体投资者合法权益。关于相关责任保险事宜，公司将遵照监管要求，结合自身经营治理实际情况，统筹研判、适时参保。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100026205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","BK0012","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609466344","title":"赛升药业：截至2026年1月30日，公司股东户数为33365","url":"https://stock-news.laohu8.com/highlight/detail?id=2609466344","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609466344?lang=zh_cn&edition=full","pubTime":"2026-02-05 11:36","pubTimestamp":1770262586,"startTime":"0","endTime":"0","summary":"证券之星消息，赛升药业(300485)02月05日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止1月31日公司股东人数是多少？谢谢！赛升药业回复：您好，截至2026年1月30日，公司股东户数为33365。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500015110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0012","BK0028","BK0239","300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608889874","title":"股市必读：赛升药业（300485）预计2025年全年扣非后净利润亏损2347.07万元至2868.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889874","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889874?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:06","pubTimestamp":1769972775,"startTime":"0","endTime":"0","summary":"来自：赛升药业预计2025年扣非后净利润亏损2347.07万元至2868.64万元，同比大幅下降。交易信息汇总1月30日主力资金净流出877.85万元；游资资金净流入115.1万元；散户资金净流入762.75万元。赛升药业发布业绩预告，预计2025年全年归属净利润盈利1377.37万元至2000万元。公司公告汇总北京赛升药业股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为1,377.37万元至2,000万元，实现扭亏为盈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300485"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607044612","title":"赛升药业（300485）披露2025年度业绩预告，1月30日股价下跌0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607044612","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607044612?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:54","pubTimestamp":1769784855,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，赛升药业报收于11.05元，较前一交易日下跌0.9%，最新总市值为53.22亿元。该股当日开盘11.15元，最高11.38元，最低10.98元，成交额达7588.03万元，换手率为2.49%。北京赛升药业股份有限公司于2026年1月30日披露《2025年度业绩预告》。公告显示，公司预计2025年度归属于上市公司股东的净利润为1,377.37万元至2,000万元，实现扭亏为盈。非经常性损益对净利润影响约为4,300万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047756.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","300485","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606219588","title":"赛升药业(300485)1月20日股东户数3.41万户，较上期减少0.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606219588","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606219588?lang=zh_cn&edition=full","pubTime":"2026-01-26 18:22","pubTimestamp":1769422979,"startTime":"0","endTime":"0","summary":"证券之星消息，近日赛升药业披露，截至2026年1月20日公司股东户数为3.41万户，较1月10日减少12.0户，减幅为0.04%。在生物制品行业个股中，赛升药业股东户数低于行业平均水平，截至1月20日，生物制品行业平均股东户数为3.44万户。从股价来看，2026年1月10日至2026年1月20日，赛升药业区间跌幅为0.52%，在此期间股东户数减少12.0户，减幅为0.04%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600025068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0012","BK0046","BK0028","300485"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775676751615,"stockEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.0555},{"period":"3month","weight":0.0142},{"period":"6month","weight":0.0133},{"period":"1year","weight":0.4388},{"period":"ytd","weight":0.0784}],"compareEarnings":[{"period":"1week","weight":0.0118},{"period":"1month","weight":-0.0248},{"period":"3month","weight":-0.0215},{"period":"6month","weight":0.0251},{"period":"1year","weight":0.27},{"period":"ytd","weight":0.0066}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京赛升药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32386人(较上一季度增加0.54%)","perCapita":"8454股","listingDate":"2015-06-26","address":"北京市大兴区北京经济技术开发区兴盛街8号","registeredCapital":"48166万元","survey":" 北京赛升药业股份有限公司的主营业务是注射针剂的研发、生产及销售。公司的主要产品是免疫系统用药、神经系统用药、心脑血管用药、其他药品、其他业务。公司免疫亲和层析规模纯化纤溶酶分离及其药学性质、药物制剂的开发研究获得北京市科学技术奖。","listedPrice":38.46},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"赛升药业,300485,赛升药业股票,赛升药业股票老虎,赛升药业股票老虎国际,赛升药业行情,赛升药业股票行情,赛升药业股价,赛升药业股市,赛升药业股票价格,赛升药业股票交易,赛升药业股票购买,赛升药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"赛升药业(300485)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供赛升药业(300485)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}